The best choices for BCE and Bell Aliant shareholders

The best choices for BCE and Bell Aliant shareholders

This special edition of “Best Canadian Stocks”  was posted in 2014 and focused a key acquisition for BCE at the time – the remaining shares of Bell Aliant Inc.
BCE INC. (Toronto symbol BCE; www.bce.ca) has agreed to pay $3.95 billion in cash and stock for the 56% of… Read More

How to choose the best investments for children

How to choose the best investments for children

Traditionally, there have been several options for parents and grandparents looking to make investments for children. But here’s how to choose the best investments for children in 2019.
Taking the time to pick the right investments for children and grandchildren is a worthwhile endeavour. If the child is under… Read More

Dividend Advisor Hotline – Friday, January 4, 2019

PFIZER INC., $43.00, New York symbol PFE, is one of the world’s largest makers of prescription drugs. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia) and Enbrel (rheumatoid arthritis).

Starting with the March 2019 payment, Pfizer will increase its quarterly dividend by 5.9%,… Read More

Cannabis in the news January 3, 2019

Read Next Article →
News on cannabis stocks and on developments in the industry haven’t let up in today’s volatile markets. Here are the stories that we believe will mean most to you as a Canadian investor.

1. The federal government’s proposed regulations for the sale of… Read More

7 ways Canadian stock options will cost you money

7 ways Canadian stock options will cost you money

Canadian stock options can generate a lot of money for your broker, but here’s seven ways they can cost you even more
Trading Canadian stock options can generate a lot of brokerage commissions, which is why some young, aggressive brokers recommend them for their clients. That’s despite… Read More

Soaring share price makes Dollarama an expensive buy

Soaring share price makes Dollarama an expensive buy

 In response to a direct “buy or not” question from a member of his Inner Circle, Pat McKeough takes a close look at Dollarama as it stands in 2017. A successful growth stock, Dollarama has risen more than 700% since it first began trading publicly. The… Read More